Literature DB >> 32537316

Oxidative Stress Alters Angiogenic and Antimicrobial Content of Extracellular Vesicles and Improves Flap Survival.

John S Mayo1, Wendy E Kurata2, Kelsey M O'Connor2, Lisa M Pierce2.   

Abstract

Extracellular vesicles (EVs) secreted from adipose-derived mesenchymal stem cells (ADSCs) (ADSC-EVs) improve flap survival after ischemia-reperfusion injury. Exposure of parent ADSCs to oxidative stress has been shown to enhance this effect, but mechanisms are unclear. We aimed to determine whether angiogenesis-promoting protein and microRNA (miRNA) content is altered in EVs after preconditioning with hydrogen peroxide (H2O2 ADSC-EVs) and whether H2O2 ADSC-EVs can increase viability of random pattern skin flaps.
METHODS: EVs secreted by human ADSCs were isolated after culture in EV-depleted medium ± H2O2. Nanoparticle tracking analysis determined size and concentration of purified EVs. Mass spectrometry and small RNA next-generation sequencing were performed to compare proteomic and miRNA profiles. ADSC-EVs, H2O2 ADSC-EVs, or vehicle were injected into random pattern skin flaps of BALB/c mice (4-5 mice per group). Viable and necrotic areas were measured on day 7, and tissues underwent histologic analysis.
RESULTS: Angiogenic and antimicrobial protein content of EVs was altered with H2O2 preconditioning. Functional enrichment analysis identified constitutive photomorphogenesis 9 signalosome (known to direct vascular endothelial growth factor production) as the major enriched Gene Ontology term unique to H2O2 ADSC-EVs. Two miRNAs were increased, and 12 (including 10 antiangiogenic miRNAs) were reduced in H2O2 ADSC-EVs. Enhanced viability (P < 0.05) of flaps treated with H2O2 ADSC-EVs compared with vehicle corresponded to increased capillary density in the H2O2 group (P < 0.001).
CONCLUSION: Altered protein and miRNA content in ADSC-EVs after H2O2 pretreatment likely contributes to enhanced therapeutic effects on flap survival observed in preclinical models.
Copyright © 2019 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons.

Entities:  

Year:  2019        PMID: 32537316      PMCID: PMC7288884          DOI: 10.1097/GOX.0000000000002588

Source DB:  PubMed          Journal:  Plast Reconstr Surg Glob Open        ISSN: 2169-7574


INTRODUCTION

Flap necrosis is a serious complication following reconstructive surgery for soft tissue coverage, with treatment at times requiring a return to the operating room or prolonged wound care.[1] Inadequate neovascularization and insufficient production of pro-angiogenic mediators are likely culprits for the poor healing. Injection of adipose-derived mesenchymal stem cells (ADSCs) into skin flaps has been shown by several investigators to increase flap survival and angiogenesis in various skin flap models.[2-5] Recently, extracellular vesicles (EVs) released from ADSCs as a cell-free alternative were also found to improve flap viability after ischemia–reperfusion injury.[6] Bai et al determined that exposure of parent ADSCs to oxidative stress via a low concentration of hydrogen peroxide (H2O2) enhanced the angiogenic effects of the EVs, but the mechanisms by which this occurs remain unclear.[7] The beneficial effects of mesenchymal stem cell (MSC)-based therapies have been proposed to be mediated predominantly by paracrine activity, to include soluble factors and EVs secreted from MSCs.[8-11] EVs are composed of different types of vesicles including exosomes (40–200 nm), which are of endosomal origin, and microvesicles (150–1,000 nm), which directly bud from the cell membrane.[8-11] Because current isolation methods cannot physically separate exosomes from small microvesicles, the term “EVs” in this manuscript refers to vesicles in the size range of exosomes. MSCs have been shown to release EVs that can selectively package and transfer proteins, nucleic acids including microRNAs (miRNAs), and lipids to injured tissues which are capable of modulating gene expression and the biological activity of recipient cells.[8-11] MiRNAs are an important class of highly conserved, small (~22 nucleotide), nonprotein-coding RNAs that regulate gene expression via degradation or translational repression of their targeted mRNA transcripts.[12] They are significant modulators of numerous fundamental physiological and cellular processes including angiogenesis, and their dysregulation is implicated in several diseases.[12,13] Results from several studies indicate that angiogenesis-related miRNAs and proteins are the main components in EVs to exert their pro-angiogenic function (reviewed in Bian et al)[14] ADSC-EVs are enriched with specific protein and miRNA cargo molecules that simultaneously activate their related signal pathway to regulate the expression of angiogenic factors in endothelial cells.[13-17] EV cargo can change in response to different microenvironments, for example, EVs secreted under hypoxic conditions have been shown to contain increased expression of platelet-derived growth factor, epidermal-derived growth factor, fibroblast growth factor, and nuclear factor kappaB signaling pathway proteins and pro-angiogenic miRNAs including miR-126, miR-130a, and miR-210.[18,19] The identity of which components of the EV proteome and miRNome responsible for the increased skin flap viability observed after H2O2 preconditioning of parent ADSCs has not been determined.[7] Therefore, the aims of this study were to (1) use unbiased proteomics and next-generation sequencing approaches to comprehensively characterize the protein and miRNA content of EVs released from human ADSCs under normal culture conditions (control ADSC-EVs) and from ADSCs preconditioned with H2O2 (H2O2 ADSC-EVs) and (2) determine whether H2O2-induced changes in EV composition can increase viability of random pattern skin flaps in an established mouse model.

MATERIALS AND METHODS

Cell Culture

Human ADSCs (ATCC PCS-500-011; American Type Culture Collection, Manassas, VA) were expanded under standard culture conditions in a complete medium [Dulbecco’s Modified Eagle’s Medium (DMEM) High Glucose (ThermoFisher Scientific, Waltham, MA)] containing 10% MSC-qualified fetal bovine serum (MilliporeSigma, Burlington, MA)/1×GlutaMAX/1×penicillin–streptomycin (ThermoFisher Scientific). These cells have been verified by ATCC to be multipotent, capable of differentiating into adipocytes, osteoblasts, and chondrocytes and analyzed using different cluster of differentiation (CD) markers to confirm that they meet MSC criteria as defined by the International Society for Cellular Therapy.[20] For isolation of control ADSC-EVs and H2O2 ADSC-EVs, culture medium was replaced with DMEM High Glucose without Phenol Red/1×GlutaMAX (ThermoFisher Scientific) containing 5% exosome-depleted fetal bovine serum (Exo-FBS; System Biosciences [SBI], Palo Alto, CA) ± 50 µM H2O2 when cells (at passage 5–8) reached 60%–80% confluence. Cells were cultured for an additional 65 hours, and then the medium was collected and stored at –80°C until EV isolation.

Proteomic Analysis

Proteomic analysis of control ADSC-EVs and H2O2 ADSC-EVs was performed by SBI utilizing SBI’s ExoMS Total Exosome Protein Profiling Service. Briefly, EVs were isolated using an affinity purification strategy to remove free protein. Isolated EVs were lysed in a gel-loading buffer, and the protein concentration was determined by Qubit protein assay (ThermoFisher Scientific). EV proteins (10 µg) were processed for gel-based extraction and trypsinization to generate peptidic libraries for liquid chromatography/mass spectrometry matrix-assisted laser desorption/ionization-time-of-flight and electrospray ionization-time-of-flight mass spectrometry. Half of the gel digest was analyzed by nano-LC-MS/MS with a Waters NanoAcquity HPLC system interfaced to a ThermoFisher Q Exactive mass spectrometer. Peptides were loaded on a trapping column and eluted over a 75-µm analytical column at 350 nL/min; both columns were packed with Luna C18 resin (Phenomenex, Torrance, CA). The mass spectrometer was operated in data-dependent mode, with the Orbitrap operating at 70,000 full width at half maximum and 17,500 full width at half maximum for MS and MS/MS, respectively. The 15 most abundant ions were selected for MS/MS. Peptide signatures were mapped to a database of known protein sequences (SwissProt Human) using Mascot (Matrix Science, Boston, MA). Mascot DAT files were parsed into Scaffold Proteome Software (Portland, OR) for validation, filtering, and to create a nonredundant list per sample. Data were filtered using 1% protein and peptide false discovery rate and requiring at least 2 unique peptides per protein. Normalized spectral abundance factor (NSAF) values were calculated based on the equation: NSAF = (SpC/MW)/Σ(SpC/MW)N, where SpC is the spectral counts, MW is the protein molecular weight in kDa, and N is the total number of proteins. NSAF values were used to approximate the relative abundance of proteins within a given sample, and relative abundance of a given protein between samples. Functional Gene Ontology (GO) enrichment analysis of identified proteins was performed using the Functional Annotation Clustering Tool in the Database for Annotation, Visualization and Integrated Discovery (DAVID Bioinformatics Resource 6.8) using default settings.[21,22]

RNA Sequencing Analysis

Next-generation sequencing (NGS) of control ADSC-EVs and H2O2 ADSC-EVs was performed by SBI utilizing SBI’s Exosome RNA NGS Service. Briefly, EVs were isolated using SBI’s ExoQuick precipitation method, and RNA was extracted using the SeraMir Exosome RNA Purification Column Kit (SBI). Measurement of small RNA concentration was determined using a Bioanalyzer 2100 instrument with the Agilent Small RNA Kit (Agilent Technologies, Santa Clara, CA). Small RNA libraries were constructed with the CleanTag Small RNA Library Preparation Kit (TriLink Biotechnologies, San Diego, CA). The final purified library was quantified with the High Sensitivity DNA Kit (Agilent Technologies). The libraries were pooled, and the 140–300-bp region was size selected on an 8% TBE (tris-borate-ethylenediaminetetraacetic acid) gel. The size-selected library was quantified with the High Sensitivity DNA 1000 Screen Tape Kit (Agilent Technologies) and the TailorMix HT1 qPCR Assay (SeqMatic, Fremont, CA), followed by a NextSeq High Output single-end sequencing run at SR75 using NextSeq 500/550 High Output v2 Kit (Illumina, San Diego, CA) at a depth of 5–15 million reads per sample. Data analysis was conducted using the Banana Slug Exosome RNA-seq Analysis platform using the human reference GRCh37/hg19 assembly (UCSC Genome Bioinformatics, Santa Cruz, CA). Differentially expressed miRNAs were identified using the DESeq package and reported as fold change >2 with significance considered at P < 0.01 (adjusted for multiple comparisons). To determine the biological significance of differentially expressed EV miRNAs, TargetScan Release 7.2 was used to generate a list of predicted miRNA targets.[23] A cutoff of ≤ –0.3 cumulative weighted context ++ score was used to exclude weak predictions. GO enrichment analysis of predicted target genes was performed using DAVID.[21,22]

EV Isolation (Animal Experiments)

Cell debris was removed by centrifugation at 300g for 10 minutes and then 3,000g for 30 minutes. Medium was passed through a 0.22-µm filter and concentrated using a 10-kDa molecular weight Amicon Ultra-15 Centrifugal Filter (MilliporeSigma). EVs were isolated from the supernatants using ExoQuick-TC Ultra precipitation solution (SBI) according to the manufacturer’s protocol and aliquots stored at –80°C before use. Aliquots of EVs were diluted in phosphate-buffered saline, and EV size and concentration were determined using nanoparticle tracking analysis by means of a NanoSight NS300 (Malvern Panalytical, Malvern, UK). Nanoparticle tracking analysis estimated the peak size of ADSC-EVs as 126 ± 8 nm and H2O2 ADSC-EVs as 150 ± 29 nm (n = 3 batches). Total protein concentration of EVs was determined by Qubit protein assay (ThermoFisher Scientific).

Random Pattern Skin Flap Model and In Vivo Study Design

The efficacy of control ADSC-EVs and H2O2 ADSC-EVs to improve viability of random pattern skin flaps was examined using an established mouse model.[2,24] The study protocol was approved by the Institutional Animal Care and Use Committee at Tripler Army Medical Center. Investigators complied with the policies as prescribed in the US Department of Agriculture Animal Welfare Act and the National Research Council’s Guide for the Care and Use of Laboratory Animals. Facilities are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. A total of 14 male BALB/c mice (9–12 weeks old, Charles River Laboratories, Wilmington, MA) were used. Cranially based, dorsal 4 cm × 2 cm random pattern skin flaps beginning 1 cm caudal to the occipital neckline were raised in mice deeply anesthetized under isoflurane inhalation. To help create a reliable ischemic gradient from the flap base, axial vessels (if present) were crushed and a medical grade silicone sheet (approximately 0.13 mm thick) was inserted to separate the flap and avoid neovascularization from the bed. The flap was sutured in place with 4-0 nylon and left without a dressing. Animals then received intradermal injections (300 µL total volume) of control ADSC-EVs (3 × 1010 particles; n = 4 mice), H2O2 ADSC-EVs (3 × 1010 particles; n = 5 mice), or vehicle (n = 5 mice) at approximately 10 points throughout the proximal, middle, and distal regions of the flap. Although H2O2 stimulation increased the number of EVs 2.5 ± 0.4-fold (n = 3 batches), particle number was adjusted to inject equal numbers of EVs per group. Buprenorphine was administered subcutaneously (0.05 mg/kg) during surgery and orally (0.4 mg/kg mixed in 2 g/kg of hazelnut spread) every 12 hours for 2 days. On day 7, mice were euthanized and flaps were photographed with a ruler in the field of view to enable calibration. Flap survival was determined grossly based on color, texture, and overall appearance. Sizes of viable and necrotic areas were measured using digital image analysis by 2 observers (ImageJ software, National Institutes of Health). A tissue biopsy (1 cm2) was taken 3 mm proximal to the necrotic margin on the viable side and processed for histology.

Histologic Analysis

Tissues were fixed in formalin and embedded in paraffin, and serial sections (5 µm) were stained with hematoxylin–eosin. The number of capillaries per high-power field (400× magnification) were counted in a minimum of 10 fields per section by 2 blinded investigators and averaged.

Statistical Analysis

Data are reported as mean ± standard error of the mean. GO enrichment analysis in DAVID used a modified Fisher’s exact test to determine whether genes were enriched in the annotation categories, and enrichment statistics were adjusted for multiple hypothesis testing by the Benjamini correction. All other statistical analyses were performed using SigmaPlot 11.2 software (Systat Software, San Jose, CA) with P < 0.05 considered significant. Comparisons among groups (viability measurements and capillary density) were made using 1-way analysis of variance (ANOVA) followed by multiple comparison testing (Holm-Sidak method) to assess differences between individual pairs of means among the groups.

RESULTS

Protein Content of ADSC-EVs and H2O2 ADSC-EVs

To analyze the protein content of EVs produced by ADSCs with or without H2O2 stimulation, MS analysis of the proteome of control ADSC-EVs and H2O2 ADSC-EVs was performed. As demonstrated in the Venn diagram (Fig. 1), 68 proteins were common to both groups, 40 proteins were found only in control ADSC-EVs, and 18 proteins were found only in H2O2 ADSC-EVs. Functional GO enrichment analysis using DAVID software revealed that approximately 87% of identified proteins in both groups were associated with the GO term extracellular exosome (Benjamini P value control ADSC-EVs = 2.64 × 10–55, H2O2 ADSC-EVs = 1.47 × 10–45). Altogether, 40%–50% of identified proteins were classified as secreted proteins. The most highly enriched biological processes common to both groups were extracellular matrix organization and keratinocyte differentiation (Tables 1 and 2). Enriched GO biological processes unique to control ADSC-EVs included innate immune response and phagocytosis (Table 3). Interestingly, the major enriched GO term unique to H2O2 ADSC-EVs that remained significant after the adjustment for multiple hypothesis testing using the conservative Benjamini correction was constitutive photomorphogenesis 9 (COP9) signalosome, which directs the production of vascular endothelial growth factor (Table 4).[25]
Fig. 1.

Venn diagram illustrating common and unique proteins in control ADSC-EVs and H2O2 ADSC-EVs.

Table 1.

Functional Annotation Clustering Analysis of Control ADSC-EV Proteome

TermCount%PBenjamini P
Functional annotation cluster 1 enrichment score: 16.76
 GO:0005615 extracellular space5854.76.73E-377.14E-35
 GO:0005576 extracellular region5249.12.05E-261.09E-24
 UP_KEYWORDS secreted53508.49E-261.96E-23
 UP_KEYWORDS signal5148.12.62E-102.01E-08
 UP_KEYWORDS glycoprotein5047.22.14E-088.23E-07
Functional annotation cluster 2 enrichment score: 6.93
 GO:0018149 peptide cross-linking109.41.91E-115.65E-09
 GO:0030216 keratinocyte differentiation1110.43.63E-118.04E-09
 GO:0031424 keratinization76.64.85E-077.16E-05
 GO:0008544 epidermis development87.59.47E-071.20E-04
Functional annotation cluster 3 enrichment score: 5.55
 UP_KEYWORDS extracellular matrix1312.38.11E-094.68E-07
 GO:0030198 extracellular matrix organization1211.33.59E-086.35E-06
 GO:0005518 collagen binding54.74.73E-040.0083
Functional annotation cluster 4 enrichment score: 5.49
 GO:0010951 negative regulation of endopeptidase activity1312.31.11E-114.93E-09
 GO:0004867 serine-type endopeptidase inhibitor activity98.51.25E-071.44E-05
 UP_KEYWORDS protease inhibitor98.52.37E-076.83E-06
Functional annotation cluster 5 enrichment score: 4.54
 GO:0044267 cellular protein metabolic process87.58.56E-068.42E-04
Functional annotation cluster 6 enrichment score: 4.4
 GO:0002576 platelet degranulation87.53.47E-063.84E-04
 GO:0031093 platelet alpha granule lumen65.71.60E-052.60E-04
 GO:0005577 fibrinogen complex32.80.00110.0128
Functional annotation cluster 7 enrichment score: 3.87
 GO:0007155 cell adhesion1211.31.28E-040.0075
Functional annotation cluster 8 enrichment score: 3.54
 UP_KEYWORDS antimicrobial76.61.92E-052.33E-04
 GO:0050832 defense response to fungus43.86.06E-040.0221
 GO:0042742 defense response to bacterium65.70.00210.0543
Functional annotation cluster 9 enrichment score: 3.15
 GO:0016209 antioxidant activity54.75.65E-062.60E-04
 GO:0000302 response to reactive oxygen species54.79.67E-050.0071
Functional annotation cluster 10 enrichment score: 3.04
 GO:0051092 positive regulation of NFκB transcription factor activity76.61.77E-040.0092
 GO:0006954 inflammatory response109.45.76E-040.0219
 UP_KEYWORDS innate immunity76.60.00220.0150

NFκB, nuclear factor kappaB.

Table 2.

Functional Annotation Clustering Analysis of H2O2 ADSC-EV Proteome

TermCount%PBenjamini P
Functional annotation cluster 1 enrichment score: 9.33
 GO:0005615 extracellular space4148.21.86E-231.21E-21
 GO:0005576 extracellular region3743.57.46E-175.33E-15
 UP_KEYWORDS secreted34403.20E-136.90E-11
 UP_KEYWORDS signal3642.45.91E-061.42E-04
 UP_KEYWORDS glycoprotein3642.44.52E-056.50E-04
Functional annotation cluster 2 enrichment score: 7.66
 UP_KEYWORDS heparin binding910.62.70E-092.92E-07
 GO:0030198 extracellular matrix organization1214.13.21E-097.93E-07
 GO:0008201~heparin binding910.61.18E-061.37E-04
Functional annotation cluster 3 enrichment score: 5.48
 UP_KEYWORDS extracellular matrix1214.18.04E-095.79E-07
 GO:0030198 extracellular matrix organization1214.13.21E-097.93E-07
 GO:0001501 skeletal system development89.45.11E-064.73E-04
Functional annotation cluster 4 enrichment score: 4.61
 GO:0018149 peptide cross-linking910.61.14E-104.24E-08
 GO:0030216 keratinocyte differentiation89.49.25E-081.71E-05
 GO:0008544 epidermis development78.23.89E-064.12E-04
Functional annotation cluster 5 enrichment score: 4.3
 GO:0010951 negative regulation of endopeptidase activity1214.11.79E-111.32E-08
 GO:0004867 serine-type endopeptidase inhibitor activity78.28.14E-063.77E-04
Functional annotation cluster 6 enrichment score: 3.55
 GO:0005178 integrin binding67.11.67E-040.0035
 GO:0005518 collagen binding55.92.15E-040.0041
 GO:0007155 cell adhesion1011.84.32E-040.0198
Functional annotation cluster 7 enrichment score: 3.39
 GO:0098609 cell–cell adhesion89.43.85E-040.0202
Functional annotation cluster 8 enrichment score: 3.06
 GO:0004866 endopeptidase inhibitor activity78.23.95E-089.16E-06
 GO:0030449 regulation of complement activation44.74.29E-040.0210
 UP_KEYWORDS inflammatory response55.90.00350.0276
Functional annotation cluster 9 enrichment score: 2.80
 GO:0042744 hydrogen peroxide catabolic process55.92.53E-063.13E-04
 GO:0000302 response to reactive oxygen species44.79.36E-040.0400
Functional annotation cluster 10 enrichment score: 2.14
 GO:0001501 skeletal system development89.45.11E-064.73E-04
 GO:0030199 collagen fibril organization44.79.36E-040.0400
 GO:0005788 endoplasmic reticulum lumen67.10.00190.0196
Table 3.

Functional Annotation Clustering Analysis of Proteins Unique to Control ADSC-EVs

TermCount%PBenjamini P
Functional annotation cluster 1 enrichment score: 8.65
 GO:0005615 extracellular space2359.07.32E-164.15E-14
 UP_KEYWORDS secreted2461.51.15E-141.60E-12
 GO:0005576 extracellular region2359.03.17E-141.13E-12
 UP_KEYWORDS signal2153.89.27E-064.33E-04
 UP_KEYWORDS glycoprotein2153.83.75E-050.0011
Functional annotation cluster 2 enrichment score: 3.01
 GO:0006911 phagocytosis, engulfment512.81.11E-064.53E-04
 GO:0006910 phagocytosis, recognition410.33.37E-050.0046
 GO:0045087 innate immune response820.54.37E-050.0044
 UP_KEYWORDS immunoglobulin C region37.73.43E-040.0080
Functional annotation cluster 3 enrichment score: 1.82
 GO:0005925 focal adhesion615.40.00120.0165
 GO:0005509 calcium ion binding718.00.00380.1011
Functional annotation cluster 4 enrichment score: 1.56
 GO:0045087 innate immune response820.54.37E-050.0044
 UP_KEYWORDS innate immunity410.30.01230.1341
 UP_KEYWORDS inflammatory response37.70.03200.2237
Functional annotation cluster 5 enrichment score: 1.28
 GO:0000502 proteasome complex37.70.00690.0718
 GO:0043488 regulation of mRNA stability37.70.02270.5135
Table 4.

Functional Annotation Clustering Analysis of Proteins Unique to H2O2 ADSC-EVs

TermCount%PBenjamini P
Functional annotation cluster 1 enrichment score: 1.75
 GO:0008180 COP9 signalosome316.74.79E-040.0088
 UP_KEYWORDS nucleotide binding633.30.01250.2309
 UP_KEYWORDS ATP binding527.80.02430.3474
Functional annotation cluster 2 enrichment score: 1.73
 UP_KEYWORDS Ubl conjugation633.30.01030.3019
 UP_KEYWORDS isopeptide bond527.80.012180.2729
Functional annotation cluster 3 enrichment score: 1.59
 UP_KEYWORDS acetylation1055.66.51E-040.0654
 UP_KEYWORDS methylation527.80.00800.3401
 UP_KEYWORDS Ubl conjugation633.30.01030.3019
 GO:0098609 cell–cell adhesion316.70.03010.8627
 GO:0098641 cadherin binding involved in cell–cell adhesion316.70.03380.8172
Functional annotation cluster 4 enrichment score: 1.28
 GO:0006413 translational initiation316.70.00830.5560
 GO:0044822 poly(A) RNA binding527.80.02350.9050
Functional annotation cluster 5 enrichment score: 1.26
 GO:0005576 extracellular region844.43.64E-040.0089
 GO:0005615 extracellular space633.30.00640.0905
 GO:0010951 negative regulation of endopeptidase activity316.70.00650.7210
Functional Annotation Clustering Analysis of Control ADSC-EV Proteome NFκB, nuclear factor kappaB. Functional Annotation Clustering Analysis of H2O2 ADSC-EV Proteome Functional Annotation Clustering Analysis of Proteins Unique to Control ADSC-EVs Functional Annotation Clustering Analysis of Proteins Unique to H2O2 ADSC-EVs Venn diagram illustrating common and unique proteins in control ADSC-EVs and H2O2 ADSC-EVs. Seventeen proteins identified in both groups that were altered >2-fold in H2O2 ADSC-EVs are listed in Table 5. Twelve (71%) of these proteins are involved in angiogenesis, and 8 (47%) have antimicrobial properties. Angiogenesis-promoting proteins enriched in H2O2 ADSC-EVs included transforming growth factor-beta-induced protein ig-h3, inter-alpha-trypsin inhibitor heavy chain H2, periostin, and pentraxin-related protein PTX3.[26-30]
Table 5.

Proteins Identified in Both Control ADSC-EVs and H2O2 ADSC-EVs that Were Altered (>2-Fold Change) in H2O2 ADSC-EVs

Proteins Upregulated in H2O2-ADSC-EVsAbbreviationMW (kDa)UniProtKB Acc. #*Fold ChangeFunctionReference
Histone H4H4_HUMAN11P628054.35Major antimicrobial peptide on skin released from sebaceous glands31
Transforming growth factor-beta-induced protein ig-h3BGH3_HUMAN75Q155823.59Collagen-binding extracellular matrix protein; involved in vascular remodeling; pro-angiogenic26
Inter-alpha-trypsin inhibitor heavy chain H2ITIH2_HUMAN106P198232.63Serum protein that promotes hyaluronan-mediated angiogenesis in tissue injury27
Filaggrin-2FILA2_HUMAN248Q5D8622.39Essential for normal keratinocyte differentiation; C-terminal fragments are antimicrobial peptides32, 33
PeriostinPOSTN_HUMAN93Q150632.39Extracellular matrix protein that promotes angiogenesis and tissue repair28
Thrombospondin-1TSP1_HUMAN129P079962.32Potent endogenous inhibitor of angiogenesis34
Pentraxin-related protein PTX3PTX3_HUMAN42P260222.22Pattern recognition molecule of innate immune system; promotes angiogenesis after stroke29, 30
Annexin A5ANXA5_HUMAN36P087582.09Inhibits tumor angiogenesis; probe for apoptosis35
Proteins Downregulated in H2O2-ADSC-EVsAbbreviationMW (kDa)UniProtKB Acc. #Fold ChangeFunctionReference
Plakophilin-1PKP1_HUMAN83Q13835–5.56Structural component of desmosomes important for cell–cell adhesion36
Vitamin D-binding proteinVTDB_HUMAN53P02774–2.65Inhibits angiogenesis; antiendothelial activity37
Apolipoprotein B-100APOB_HUMAN516P04114–2.65Contains cryptic host defense peptides38
LactotransferrinTRFL_HUMAN78P02788–2.51Inhibits angiogenesis in colon tumor model; iron-binding antimicrobial protein39, 40
SerotransferrinTRFE_HUMAN77P02787–2.51Inhibits angiogenesis in pancreatic tumor model; iron-binding antimicrobial protein41, 42
Alpha-fetoproteinFETA_HUMAN69P02771–2.51Modulates expression of VEGF; pro-angiogenic43
Fatty acid-binding protein 5FABP5_HUMAN15Q01469–2.09Promotes angiogenesis and activates IL6/STAT3/VEGFA pathway44
DermcidinDCD_HUMAN11P81605–2.09Antimicrobial peptide45
HornerinHORN_HUMAN282Q86YZ3–2.08Protein in skin that contains cationic antimicrobial peptides; pro-angiogenic46, 47

*UniProtKB Acc. #, UniProt Knowledgebase Accession Number.

Proteins Identified in Both Control ADSC-EVs and H2O2 ADSC-EVs that Were Altered (>2-Fold Change) in H2O2 ADSC-EVs *UniProtKB Acc. #, UniProt Knowledgebase Accession Number.

MiRNA Content of ADSC-EVs and H2O2 ADSC-EVs

A total of 495 and 454 known miRNAs were identified in control ADSC-EVs and H2O2 ADSC-EVs, respectively. Using a cutoff of >2-fold change and P < 0.01, 2 miRNAs were increased and 12 miRNAs (including 10 antiangiogenic miRNAs) were reduced in H2O2 ADSC-EVs (Table 6). Evaluation of putative target mRNAs using TargetScan Release 7.2 identified 980 predicted gene targets of these differentially expressed miRNAs. Functional GO enrichment analysis of constructed gene sets in DAVID identified the most highly enriched biological processes as transcription from RNA polymerase II promoter and embryonic skeletal system morphogenesis (Table 7).
Table 6.

Differentially Expressed miRNAs (>2-Fold Change, P < 0.01) in H2O2 ADSC-EVs Compared to Control ADSC-EVs

miRNAFold ChangeNormalized AbundanceControl ADSC-EVsNormalized Abundance H2O2 ADSC-EVsPRole in AngiogenesisReference
hsa-miR-10395-5p13.762.1729.860.0007Unknown
hsa-miR-10395-3p13.562.1729.420.0008Unknown
hsa-miR-24-3p–3.42397.69116.12<0.0001Antiangiogenic13
hsa-miR-16-5p–3.0875.2324.440.0025Antiangiogenic13
hsa-miR-93-5p–2.6488.6533.530.0044Pro-angiogenic48
hsa-miR-31-5p–2.56509.43199.31<0.0001Pro-angiogenic, antiangiogenic49, 50
hsa-miR-23a-3p–2.46441.80179.85<0.0001Pro-angiogenic13
hsa-miR-152-3p–2.27156.9569.070.0011Antiangiogenic51
hsa-miR-122-5p–2.23894.20401.27<0.0001Antiangiogenic52
hsa-miR-134-5p–2.19223.78102.320.0064Antiangiogenic53
hsa-miR-221-3p–2.1912206.985582.17<0.0001Antiangiogenic13
hsa-miR-196a-5p–2.17173.5579.870.0063Antiangiogenic54
hsa-miR-23b-3p–2.11255.23120.970.0005Antiangiogenic55
hsa-miR-222-3p–2.11871.46413.91<0.0001Antiangiogenic13
Table 7.

Biological Processes Enriched among the Genes Predicted to Be Targeted by miRNAs that Were Downregulated (>2-Fold Change, P < 0.01) in H2O2 ADSC-EVs Compared to Control ADSC-EVs

GO TermCount%PBenjamini P
GO:0006366 transcription from RNA polymerase II promoter535.42.75E-060.0092
GO:0048704 embryonic skeletal system morphogenesis121.22.95E-060.0050
GO:0045893 positive regulation of transcription, DNA templated525.36.66E-060.0075
GO:0009952 anterior/posterior pattern specification161.61.28E-050.0108
GO:1900740 positive regulation of protein insertion into
Mitochondrial membrane involved in apoptotic signaling pathway101.01.36E-050.0092
GO:0014911 positive regulation of smooth muscle cell migration80.84.15E-050.0232
GO:0008284 positive regulation of cell proliferation464.74.27E-050.0205
GO:0048863 stem cell differentiation90.94.58E-050.0192
GO:0045944 positive regulation of transcription from RNA
Polymerase II promoter808.25.72E-050.0213
GO:0030335 positive regulation of cell migration242.48.03E-050.0269
GO:0000122 negative regulation of transcription from RNA
Polymerase II promoter626.31.01E-040.0307
GO:0006468 protein phosphorylation444.51.08E-040.0300
Differentially Expressed miRNAs (>2-Fold Change, P < 0.01) in H2O2 ADSC-EVs Compared to Control ADSC-EVs Biological Processes Enriched among the Genes Predicted to Be Targeted by miRNAs that Were Downregulated (>2-Fold Change, P < 0.01) in H2O2 ADSC-EVs Compared to Control ADSC-EVs

Flap Survival and Capillary Density

On postoperative day 7, survival area was significantly larger in skin flaps of mice treated with H2O2 ADSC-EVs compared with vehicle (P = 0.04, ANOVA; Figs. 2 and 3). Increased capillary density was observed in the H2O2 ADSC-EV group compared to that in the other groups (P < 0.001, ANOVA; Figs. 4 and 5). Increased vessel diameter was also apparent in tissues treated with H2O2 ADSC-EVs (Fig. 5).
Fig. 2.

Quantitative analysis of skin flap survival area. *P < 0.05 vs vehicle.

Fig. 3.

Representative images of skin flaps injected with vehicle (A), control ADSC-EVs (B), and H2O2 ADSC-EVs (C) (elevated to display the underside) on postoperative day 7. Note the increased area of viable tissue within the flap treated with H2O2 ADSC-EVs (C).

Fig. 4.

Quantitative analysis of capillary density. *P < 0.05 vs vehicle and control ADSC-EVs.

Fig. 5.

Representative hematoxylin–eosin-stained sections of skin flaps injected with vehicle (A), control ADSC-EVs (B), and H2O2 ADSC-EVs (C). Top panels are magnified views of corresponding boxes in bottom panels. Scale bar = 50 µm. Blood vessels are denoted by *.

Quantitative analysis of skin flap survival area. *P < 0.05 vs vehicle. Representative images of skin flaps injected with vehicle (A), control ADSC-EVs (B), and H2O2 ADSC-EVs (C) (elevated to display the underside) on postoperative day 7. Note the increased area of viable tissue within the flap treated with H2O2 ADSC-EVs (C). Quantitative analysis of capillary density. *P < 0.05 vs vehicle and control ADSC-EVs. Representative hematoxylin–eosin-stained sections of skin flaps injected with vehicle (A), control ADSC-EVs (B), and H2O2 ADSC-EVs (C). Top panels are magnified views of corresponding boxes in bottom panels. Scale bar = 50 µm. Blood vessels are denoted by *.

DISCUSSION

The use of stem cell-derived EVs has gained much attention as an emerging approach for therapeutic angiogenesis in ischemic diseases.[14] In fact, EVs are currently being tested in clinical trials in patients with acute ischemic stroke, type 1 diabetes mellitus, and macular holes.[8] Recently, Bai et al determined that preconditioning ADSCs with a low concentration of H2O2 improved the pro-angiogenic properties of secreted EVs in vitro and in vivo in a model of skin flap transplantation, suggesting that H2O2 may induce EVs to exhibit an enhanced pro-angiogenic capacity for cell-free therapeutic applications.[7] In this study, comprehensive proteomic and miRNA analyses revealed that exposure to an H2O2-induced oxidative stress microenvironment altered the expression of several angiogenic and antimicrobial proteins and miRNAs in ADSC-EVs. We also verified that H2O2 ADSC-EVs increased microvascular density and viability of random pattern skin flaps in vivo. Functional enrichment analysis of proteins found only in H2O2 ADSC-EVs identified COP9 signalosome as the primary enriched GO term unique to H2O2 ADSC-EVs. The COP9 signalosome is a highly conserved multimeric protein complex with kinase activity that cooperates with the ubiquitin/26S proteasome system in the regulation of stability of important cellular proteins.[25] The COP9 signalosome has been shown to direct the production of vascular endothelial growth factor, a major mediator of angiogenesis, through c-Jun signaling in tumor cells, thereby promoting angiogenesis.[25] Upregulation of proteins involved in this complex therefore may be 1 mechanism by which H2O2 ADSC-EVs enhance angiogenesis. Angiogenesis is well known to be a complex process that is regulated by a variety of angiogenic stimulators and inhibitors.[13] H2O2 pretreatment resulted in the upregulation and downregulation of several pro-angiogenic and antiangiogenic proteins and miRNAs (listed in Tables 5 and 6), thereby influencing this intricate balance. Angiogenesis-promoting proteins enriched in ADSC-EVs after H2O2 stimulation included the extracellular matrix proteins periostin and transforming growth factor-beta-induced protein ig-h3, and pentraxin-related protein PTX3 and inter-alpha-trypsin inhibitor heavy chain H2, previously shown to promote wound healing and vascular remodeling.[26-30] Of the 14 differentially expressed miRNAs, 10 are considered to be antiangiogenic and all were downregulated in H2O2 ADSC-EVs, consequently increasing angiogenesis via release of inhibition.[13,50-55] Both groups contained known pro-angiogenic miRNAs that were not differentially expressed such as abundant levels of miR-21. MiR-21 has been shown to have antibacterial, antiinflammatory, and proliferative roles in a diabetic infected wound model and has been proposed as a promising intervention target for the treatment of refractory wounds such as diabetic foot ulcers.[56] Results from this study also suggest that ADSC-EVs may benefit wound healing and infection prevention of skin flaps through their antimicrobial peptide content. Twenty-four antimicrobial peptides and proteins important in innate immunity were identified in ADSC-EVs, including dermcidin, lipocalin-1, lysozyme C, neutrophil defensin 1, prolactin-inducible protein, psoriasin (S100A7), calprotectin (S100A8/A9), histone H4, lactotransferrin, and hornerin, to name a few. These peptides are known to have activities against various Gram-positive and Gram-negative bacteria, viruses, and fungi, and likely are responsible for the antimicrobial properties of MSCs observed by us and others.[57,58] Some of these peptides have been identified in sweat EVs, suggesting a role in skin immunity.[59] Although it has been postulated that MSC-EVs contain active agents with potential antimicrobial effects, a paucity of data exists regarding the antimicrobial peptide cargo of ADSC-EVs and how it may be affected by different microenvironments.[60] In general, antimicrobial peptides and proteins were reduced in H2O2 ADSC-EVs. However, histone H4 and filaggrin-2, whose peptides are important in antimicrobial defense of the skin, were upregulated in H2O2 ADSC-EVs.[31-33] Interestingly, pentraxin-related protein PTX3, which was also upregulated in H2O2 ADSC-EVs, is an essential soluble pattern recognition molecule of the innate immune system and a key regulator of angiogenesis that exerts dual functions involving both antimicrobial resistance and tissue repair.[29,30] Although the therapeutic benefits of EVs seem highly encouraging in preclinical models, technical challenges currently exist in this exciting new field that must be resolved before EV-based therapeutics may be incorporated into clinical practice. One of the major challenges is the efficient production of EVs in a clinically applicable scale. Other obstacles include a lack of consensus (1) on the best method to isolate and purify EVs, (2) on the compositions of EVs from different sources or different culture conditions, and (3) as to how to quantitate the EVs.[61] Nevertheless, Mendt et al in conjunction with Codiak Biosciences have recently developed a process for the production of Good Manufacturing Practice-grade EVs derived from MSCs.[62] Using a Quantum bioreactor culture system, they demonstrated successful Good Manufacturing Practice-grade production, scalability, EV stability, and consistent in vitro and in vivo efficacy in preclinical models of pancreatic cancer.[62] In addition, EVs can be lyophilized and stored at 4°C without compromising stability for 36 months and are easily reconstituted, thereby demonstrating great promise as an “off-the-shelf” therapeutic.

CONCLUSIONS

ADSC-EVs hold immense potential as an allogeneic, “off-the-shelf” cell-free therapeutic for skin flap transplantation offering the benefits of stem cell therapy while representing a theoretically safer alternative. The broad repertoire of angiogenic and antimicrobial proteins and miRNAs in ADSC-EVs, which are altered after H2O2 preconditioning, likely contributes to their favorable therapeutic effects observed on skin flap survival. Further investigation is needed to determine the relative importance of particular miRNAs and proteins and their affected signaling pathways in flap recovery.
  61 in total

1.  Dermcidin-derived peptides show a different mode of action than the cathelicidin LL-37 against Staphylococcus aureus.

Authors:  Ilknur Senyürek; Maren Paulmann; Tobias Sinnberg; Hubert Kalbacher; Martin Deeg; Thomas Gutsmann; Marina Hermes; Thomas Kohler; Fritz Götz; Christiane Wolz; Andreas Peschel; Birgit Schittek
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

2.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

3.  Adipose mesenchymal stem cell-derived exosomes stimulated by hydrogen peroxide enhanced skin flap recovery in ischemia-reperfusion injury.

Authors:  Yun Bai; Yu-di Han; Xin-Long Yan; Jing Ren; Quan Zeng; Xiao-Dong Li; Xue-Tao Pei; Yan Han
Journal:  Biochem Biophys Res Commun       Date:  2018-04-14       Impact factor: 3.575

4.  Generation and testing of clinical-grade exosomes for pancreatic cancer.

Authors:  Mayela Mendt; Sushrut Kamerkar; Hikaru Sugimoto; Kathleen M McAndrews; Chia-Chin Wu; Mihai Gagea; Sujuan Yang; Elena V Rodriges Blanko; Qian Peng; Xiaoyan Ma; Joseph R Marszalek; Anirban Maitra; Cassian Yee; Katayoun Rezvani; Elizabeth Shpall; Valerie S LeBleu; Raghu Kalluri
Journal:  JCI Insight       Date:  2018-04-19

Review 5.  Lactoferrin: an iron-binding antimicrobial protein against Escherichia coli infection.

Authors:  Chih-Ching Yen; Chih-Jie Shen; Wu-Huei Hsu; Yi-Hsin Chang; Hsin-Tang Lin; Hsiao-Ling Chen; Chuan-Mu Chen
Journal:  Biometals       Date:  2011-02-16       Impact factor: 2.949

6.  Predicting effective microRNA target sites in mammalian mRNAs.

Authors:  Vikram Agarwal; George W Bell; Jin-Wu Nam; David P Bartel
Journal:  Elife       Date:  2015-08-12       Impact factor: 8.140

7.  Bone Marrow-Derived Mesenchymal Stem Cells Enhance Bacterial Clearance and Preserve Bioprosthetic Integrity in a Model of Mesh Infection.

Authors:  Erik T Criman; Wendy E Kurata; Karen W Matsumoto; Harry T Aubin; Carmen E Campbell; Lisa M Pierce
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-06-17

Review 8.  Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm.

Authors:  Kan Yin; Shihua Wang; Robert Chunhua Zhao
Journal:  Biomark Res       Date:  2019-04-04

Review 9.  Therapeutic angiogenesis using stem cell-derived extracellular vesicles: an emerging approach for treatment of ischemic diseases.

Authors:  Xiaowei Bian; Kui Ma; Cuiping Zhang; Xiaobing Fu
Journal:  Stem Cell Res Ther       Date:  2019-06-03       Impact factor: 6.832

10.  Silencing alpha-fetoprotein inhibits VEGF and MMP-2/9 production in human hepatocellular carcinoma cell.

Authors:  Wenbo Meng; Xun Li; Zhongtian Bai; Yan Li; Jinqiu Yuan; Tao Liu; Jun Yan; Wence Zhou; Kexiang Zhu; Hui Zhang; Yumin Li
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

View more
  5 in total

1.  Oxidative stress-induced endothelial cells-derived exosomes accelerate skin flap survival through Lnc NEAT1-mediated promotion of endothelial progenitor cell function.

Authors:  Linlin Guo; Yuxuan Chen; Xiaoling Feng; Di Sun; Jiaming Sun; Shan Mou; Kangcheng Zhao; Ran An
Journal:  Stem Cell Res Ther       Date:  2022-07-18       Impact factor: 8.079

2.  Priming With Toll-Like Receptor 3 Agonist Poly(I:C) Enhances Content of Innate Immune Defense Proteins but Not MicroRNAs in Human Mesenchymal Stem Cell-Derived Extracellular Vesicles.

Authors:  Lisa M Pierce; Wendy E Kurata
Journal:  Front Cell Dev Biol       Date:  2021-05-24

3.  Therapeutic Potential of Extracellular Vesicles for Sepsis Treatment.

Authors:  Stephanie M Kronstadt; Alex E Pottash; Daniel Levy; Sheng Wang; Wei Chao; Steven M Jay
Journal:  Adv Ther (Weinh)       Date:  2021-04-29

Review 4.  Stem Cell-Derived Exosome as Potential Therapeutics for Microbial Diseases.

Authors:  Somayeh Keshtkar; Maryam Kaviani; Saeede Soleimanian; Negar Azarpira; Zahra Asvar; Sara Pakbaz
Journal:  Front Microbiol       Date:  2022-02-14       Impact factor: 5.640

Review 5.  Extracellular Vesicles from Human Adipose-Derived Mesenchymal Stem Cells: A Review of Common Cargos.

Authors:  Maria Luz Alonso-Alonso; Laura García-Posadas; Yolanda Diebold
Journal:  Stem Cell Rev Rep       Date:  2021-04-26       Impact factor: 5.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.